Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review.
Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dimpy P
DP
Shah
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pankil K
PK
Shah
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jacques M
JM
Azzi
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Firas
F
El Chaer
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rfchemaly@mdanderson.org.
Roy F
RF
Chemaly
D000998:Antiviral Agents / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000821:virology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015994:Incidence; D029121:Metapneumovirus / Q000187:drug effects / Q000472:pathogenicity*; D018184:Paramyxoviridae Infections / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000821:virology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000821:virology*; D012307:Risk Factors
D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous
Cancer; Leukemia; Lymphoma; Mortality; Stem cell transplantation; hMPV